Claudia Fiorina
A5057930215- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Coronary Interventions and Diagnostics
- Heart Failure Treatment and Management
- Cardiac Structural Anomalies and Repair
- Folate and B Vitamins Research
- Antimicrobial Resistance in Staphylococcus
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular and exercise physiology
- Acute Myocardial Infarction Research
- Infectious Aortic and Vascular Conditions
- Viral Infections and Immunology Research
- Pulmonary Hypertension Research and Treatments
- Streptococcal Infections and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Mechanical Circulatory Support Devices
- Atrial Fibrillation Management and Outcomes
- Central Venous Catheters and Hemodialysis
- Cardiac electrophysiology and arrhythmias
- Takotsubo Cardiomyopathy and Associated Phenomena
- Venous Thromboembolism Diagnosis and Management
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2015-2024
University of Brescia
2008-2023
Brescia University
2022
McGill University Health Centre
2021
St. Paul's Hospital
2012-2016
Rabin Medical Center
2012-2016
EMO GVM Centro Cuore Columbus
2016
Ferrarotto Hospital
2011-2016
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016
Istituto Neurologico Mediterraneo
2016
Background— There is a lack of information on the incidence and predictors early mortality at 30 days late between 1 year after transcatheter aortic valve implantation (TAVI) with self-expanding CoreValve Revalving prosthesis. Methods Results— A total 663 consecutive patients (mean age 81.0±7.3 years) underwent TAVI third generation 18-Fr device in 14 centers. Procedural success intraprocedural were 98% 0.9%, respectively. The cumulative incidences 5.4% days, 12.2% 6 months, 15.0% year....
Owing to a considerable shift toward bioprosthesis implantation rather than mechanical valves, it is expected that patients will increasingly present with degenerated bioprostheses in the next few years. Transcatheter aortic valve-in-valve less invasive approach for structural valve deterioration; however, comprehensive evaluation of survival after procedure has not yet been performed.To determine transcatheter inside failed surgical bioprosthetic valves.Correlates were evaluated using...
Background— Transcatheter aortic valve-in-valve implantation is an emerging therapeutic alternative for patients with a failed surgical bioprosthesis and may obviate the need reoperation. We evaluated clinical results of this technique using large, worldwide registry. Methods Results— The Global Valve-in-Valve Registry included 202 degenerated bioprosthetic valves (aged 77.7±10.4 years; 52.5% men) from 38 cardiac centers. Bioprosthesis mode failure was stenosis (n=85; 42%), regurgitation...
There are limited data on coronary obstruction following transcatheter valve-in-valve (ViV) implantation inside failed aortic bioprostheses. The objectives of this study were to determine the incidence, predictors, and clinical outcomes in ViV procedures. A total 1612 procedures from Valve-in-Valve International Data (VIVID) Registry evaluated. subject centralized blinded corelab computed tomography (CT) analysis a subset patients. virtual valve ostium distance (VTC) was determined. 37...
<h3>Importance</h3> Limited data exist on clinical characteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter aortic valve replacement (TAVR). <h3>Objective</h3> To determine the associated factors, characteristics, TAVR. <h3>Design, Setting, Participants</h3> The Infectious Endocarditis TAVR International Registry included with definite from 47 centers Europe, North America, South America between June 2005 October 2015. <h3>Exposure</h3>...
The paucity of evidences about the long-term durability currently available transcatheter prostheses is one main issues aortic valve implantation (TAVI). We sought to assess 3-year clinical and echocardiographic outcomes patients undergoing TAVI with third generation CoreValve prosthesis (Medtronic Incorporation, MN, USA). From Italian registry, 181 who underwent from June 2007 August 2008 eligible for follow-up were analysed. All defined according Valve Academic Research Consortium....
Aims The aim of this study was to report the prevalence, clinical features and outcomes patients with ST-elevation myocardial infarction (STEMI) hospitalized during Corona-Virus Disease 2019 (COVID-19) outbreak compared those admitted in a previous equivalent period. Methods results Eighty-five for STEMI at high-volume Italian centre were included. Patients COVID-19 (21 February–10 April 2020) (40%) pre-COVID-19 period (3 January–20 February (60%). A 43% reduction admissions observed Time...
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There no data on long-term outcomes after ViV. Our aim was perform a large-scale assessment of survival and reintervention ViV.A total 1006 ViV performed more than 5 years ago [mean age 77.7 ± 9.7 years; 58.8% male; median STS-PROM score 7.3% (4.2-12.0)] were included in the analysis. Patients treated with Medtronic self-expandable valves (CoreValve/Evolut, Inc., Minneapolis, MN, USA)...
Background— Transcatheter valve implantation inside failed bioprosthetic surgical valves (valve-in-valve [ViV]) may offer an advantage over reoperation. Supra-annular transcatheter position be advantageous in achieving better hemodynamics after ViV. Our objective was to define targets for that would improve Methods and Results— Cases from the Valve-in-Valve International Data (VIVID) registry were analyzed using centralized core laboratory assessment blinded clinical events. Multivariate...
Background— Little is known of the prognostic significance mitral regurgitation (MR) on transcatheter aortic valve replacement (TAVR), impact TAVR MR severity, and variables associated with possible post-TAVR improvement in MR. We evaluated these issues a multicenter registry patients undergoing CoreValve Revalving System–TAVR. Methods Results— Among 1007 consecutive patients, 670 (66.5%), 243 (24.1%), 94 (9.3%) presented no/mild, moderate, severe MR, respectively. At 1 month after TAVR, or...
Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous repair or replacement. Our aim was perform a large-scale analysis examining midterm outcomes ViV ViR.Patients undergoing ViR were enrolled the Valve-in-Valve International Data Registry. Cases performed between March 2006 2020. Clinical endpoints reported according Valve Academic Research Consortium (MVARC) definitions. Significant...
Background— Transcatheter aortic valves can degenerate in a manner similar to surgical bioprostheses. Methods and Results— Clinical echocardiographic outcomes of patients who underwent redo transcatheter valve replacement (TAVR) procedures >2 weeks post procedure were collected from 14 centers. Among 13 876 patients, 50 (0.4%) TAVR at participating Indications for moderate–severe prosthetic stenosis (n=10, 21.7%), central regurgitation (n=13, 28.3%), paraprosthetic (n=25, 50.0%). The...
We sought to evaluate the outcome of transcatheter aortic valve replacement (TAVR) with CoreValve Revalving System (CRS-TAVR) in inoperable patients presenting severe regurgitation (AR), compared treated for native stenosis (AS). From October 2008 January 2013, 1,557 consecutive undergoing CRS-TAVR, whom 26 (1.6%) presented AR, were prospectively followed. Compared AS, AR significantly younger (mean age 73±10 vs. 82±6, p=0.02), more frequently NYHA Class III/IV (95% 73%, p=0.01) and had a...